Sutro Biopharma shows 210,378 shared stake (1.3%)

Sutro Biopharma files an amendment to a Schedule 13G/A reporting joint beneficial ownership of 210,378 shares of common stock, representing 1.3% of the class.

Rhea-AI Filing Summary

Sutro Biopharma files an amendment to a Schedule 13G/A reporting joint beneficial ownership of 210,378 shares of common stock, representing 1.3% of the class. The filing lists Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander as joint filers and includes a Joint Filing Agreement dated April 20, 2026.

The cover data shows the class CUSIP as 869367201 and an apparent as-of date of 03/31/2026 on the reporting header. Signatures are provided by Gil Raviv and Israel A. Englander.

Insights

Institutional Ownership Analyst

Large manager reports a small, shared stake in Sutro Biopharma.

The filing discloses that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander jointly report shared voting and dispositive power over 210,378 shares, equal to 1.3% of the outstanding common stock as stated on the cover.

The submission includes a Joint Filing Agreement dated April 20, 2026, indicating coordinated disclosure rather than an operational change. Timing and cash-flow treatment are not specified in the excerpt; subsequent filings may show transactions if holders trade these positions.

Key Figures

Shares reported: 210,378 shares Percent of class: 1.3% CUSIP: 869367201 +2 more

5 metrics

Shares reported 210,378 shares shared voting/dispositive power reported on Schedule 13G/A

Percent of class 1.3% percent of class reported on cover pages

CUSIP 869367201 Common Stock, par value $0.001 per share

Reporting header date 03/31/2026 date shown on the filing header

Joint Filing Agreement date April 20, 2026 date of Exhibit I Joint Filing Agreement

Key Terms

Schedule 13G/A, beneficial ownership, shared dispositive power, Joint Filing Agreement

4 terms

Schedule 13G/A regulatory

"Amendment No. 1 ) Sutro Biopharma, Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership financial

"Amount beneficially owned: See response to Item 9 on each cover page."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared dispositive power financial

"Shared Dispositive Power 210,378.00"

Joint Filing Agreement legal

"Exhibit I: Joint Filing Agreement, dated as of April 20, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Millennium report in Sutro Biopharma (STRO)?

Millennium reports shared beneficial ownership of 210,378 shares, or 1.3% of the class. The filing attributes shared voting and shared dispositive power to Millennium entities and Israel A. Englander as joint filers.

Who are the joint filers on the Schedule 13G/A for STRO?

The joint filers are Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. The filing includes a Joint Filing Agreement dated April 20, 2026, among those parties.

What CUSIP and reporting date are shown on the filing?

The filing lists CUSIP 869367201 and shows an as-of header date of 03/31/2026. The Joint Filing Agreement is dated April 20, 2026, per the exhibit information.

Does the Schedule 13G/A state sole voting or dispositive power?

No; the filing reports zero sole voting and sole dispositive power and shows shared voting and shared dispositive power for 210,378 shares. The securities are held by entities subject to Millennium's voting control or investment discretion.

Was a Joint Filing Agreement included with the amendment?

Yes; Exhibit I is a Joint Filing Agreement dated April 20, 2026. The agreement documents the joint filing relationship among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 05:49 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Sutro Biopharma, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

869367201

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 869367201

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 210,378.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 210,378.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

210,378.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 869367201

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 210,378.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 210,378.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

210,378.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 869367201

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 210,378.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 210,378.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

210,378.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sutro Biopharma, Inc.
(b)	Address of issuer's principal executive offices: 111 Oyster Point Boulevard, South San Francisco, California 94080
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 869367201
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	04/20/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	04/20/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	04/20/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of April 20, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.